TY - JOUR
T1 - Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms
AU - Ji, Yuan
AU - Olson, Janet
AU - Zhang, Jianping
AU - Hildebrandt, Michelle
AU - Wang, Liewei
AU - Ingle, James
AU - Fredericksen, Zachary
AU - Sellers, Thomas
AU - Miller, William
AU - Dixon, J. Michael
AU - Brauch, Hiltrud
AU - Eichelbaum, Michel
AU - Justenhoven, Christina
AU - Hamann, Ute
AU - Ko, Yon
AU - Brüning, Thomas
AU - Chang-Claude, Jenny
AU - Wang-Gohrke, Shan
AU - Schaid, Daniel
AU - Weinshilboum, Richard
PY - 2008/7/15
Y1 - 2008/7/15
N2 - Catechol O-methyltransferase (COMT)-catalyzed methylation of catecholestrogens has been proposed to play a protective role in estrogen-induced genotoxic carcinogenesis. We have taken a comprehensive approach to test the hypothesis that genetic variation in COMT might influence breast cancer risk. Fifteen COMT single nucleotide polymorphisms (SNPs) selected on the basis of in-depth resequencing of the COMT gene were genotyped in 1,482 DNA samples from a Mayo Clinic breast cancer case control study. Two common SNPs in the distal promoter for membrane-bound (MB) COMT, rs2020917 and rs737865, were associated with breast cancer risk reduction in premenopausal women in the Mayo Clinic study, with allele-specific odds ratios (OR) of 0.70 [95% confidence interval (CI), 0.52-0.95] and 0.68 (95% CI, 0.51-0.92), respectively. These two SNPs were then subjected to functional genomic analysis and were genotyped in an additional 3,683 DNA samples from two independent case control studies (GENICA and GESBC). Functional genomic experiments showed that these SNPs could up-regulate transcription and that they altered DNA-protein binding patterns. Furthermore, substrate kinetic and exon array analyses suggested a role for MB-COMT in catecholestrogen inactivation. The GENICA results were similar to the Mayo case control observations, with ORs of 0.85 (95% CI, 0.72-1.00) and 0.85 (95% CI, 0.72-1.01) for the two SNPs. No significant effect was observed in the GESBC study. These studies showed that two SNPs in the COMT distal promoter were associated with breast cancer risk reduction in two of three case control studies, compatible with the results of functional genomic experiments, suggesting a role for MB-COMT in breast cancer risk.
AB - Catechol O-methyltransferase (COMT)-catalyzed methylation of catecholestrogens has been proposed to play a protective role in estrogen-induced genotoxic carcinogenesis. We have taken a comprehensive approach to test the hypothesis that genetic variation in COMT might influence breast cancer risk. Fifteen COMT single nucleotide polymorphisms (SNPs) selected on the basis of in-depth resequencing of the COMT gene were genotyped in 1,482 DNA samples from a Mayo Clinic breast cancer case control study. Two common SNPs in the distal promoter for membrane-bound (MB) COMT, rs2020917 and rs737865, were associated with breast cancer risk reduction in premenopausal women in the Mayo Clinic study, with allele-specific odds ratios (OR) of 0.70 [95% confidence interval (CI), 0.52-0.95] and 0.68 (95% CI, 0.51-0.92), respectively. These two SNPs were then subjected to functional genomic analysis and were genotyped in an additional 3,683 DNA samples from two independent case control studies (GENICA and GESBC). Functional genomic experiments showed that these SNPs could up-regulate transcription and that they altered DNA-protein binding patterns. Furthermore, substrate kinetic and exon array analyses suggested a role for MB-COMT in catecholestrogen inactivation. The GENICA results were similar to the Mayo case control observations, with ORs of 0.85 (95% CI, 0.72-1.00) and 0.85 (95% CI, 0.72-1.01) for the two SNPs. No significant effect was observed in the GESBC study. These studies showed that two SNPs in the COMT distal promoter were associated with breast cancer risk reduction in two of three case control studies, compatible with the results of functional genomic experiments, suggesting a role for MB-COMT in breast cancer risk.
UR - http://www.scopus.com/inward/record.url?scp=48649084143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48649084143&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-08-0043
DO - 10.1158/0008-5472.CAN-08-0043
M3 - Article
C2 - 18632656
AN - SCOPUS:48649084143
SN - 0008-5472
VL - 68
SP - 5997
EP - 6005
JO - Cancer research
JF - Cancer research
IS - 14
ER -